Xenon pauses phase 3 depression trials after psychosis events
Xenon Pharmaceuticals has voluntarily paused new enrollment in its Phase 3 clinical trials for bipolar depression and major depressive disorder. The company halted the studies following neuropsychiatric side effects, specifically psychosis events. This setback occurred the same day Xenon submitted a New Drug Application to the FDA for azetukalner, a drug intended to treat focal seizures. Despite the regulatory filing for its epilepsy treatment, Xenon shares fell between 30% and 32.2% as investors reacted to the psychiatry program's instability.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Xenon paused new enrollment in Phase 3 trials for major depressive disorder and bipolar depression.
- ✓ The trial pause follows reports of psychosis events and neuropsychiatric side effects.
- ✓ Xenon submitted a New Drug Application to the FDA for azetukalner to treat focal seizures.
- ✓ Xenon stock prices dropped by approximately 30% following the trial pause.
What changed
Xenon halted new enrollment in its Phase 3 depression studies due to psychosis events while simultaneously filing an NDA for azetukalner.
Live updates
-
Xenon Pauses Phase 3 Depression Trials Over Psychosis Events
Xenon Pharmaceuticals has voluntarily paused new enrollment in its Phase 3 clinical trials for bipolar depression and major depressive disorder. The company halted the studies following neuropsychiatric side effects, specifically psychosis events. This setback occurred the same day Xenon submitted a New Drug Application to the FDA for azetukalner, a drug intended to treat focal seizures. Despite the regulatory filing for its epilepsy treatment, Xenon shares fell between 30% and 32.2% as investors reacted to the psychiatry program's instability.
Why it matters
Phase 3 trials are the final stage of testing before a drug can be approved for public use. A pause due to safety concerns can delay market entry or lead to total program termination. The company is currently balancing this setback against the potential approval of its focal seizure medication.
What is confirmed
- Xenon paused new enrollment in Phase 3 trials for major depressive disorder and bipolar depression.
- The trial pause follows reports of psychosis events and neuropsychiatric side effects.
- Xenon submitted a New Drug Application to the FDA for azetukalner to treat focal seizures.
- Xenon stock prices dropped by approximately 30% following the trial pause.
What to watch next
- FDA decision on the azetukalner NDA for focal seizures
- Xenon announcement on whether the depression trials will resume or be terminated
- Detailed safety data release regarding the neuropsychiatric events
confidence 100%Sources used for this update (8)
- Fierce Biotech — Xenon pauses phase 3 depression trials after psychosis events
- Reuters — Xenon pauses new enrollment in depression drug trials over side-effect concerns
- Yahoo Finance — XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
- Barron's — Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
- Investor's Business Daily — Why This Biotech Just Erased Its One-Day 50% Pop
- Yahoo Finance — Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
- BioPharma Dive — Xenon shares fall following depression trial pause
- finance.yahoo.com — Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community